This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Trombetta C, Piccirella S, Perini D, Kistner O, Montomoli E. Emerging influenza strains in the last two decades: a threat of a new pandemic?. Vaccines. 2015; 3:172–85.10.3390/vaccines301017226344952TrombettaCPiccirellaSPeriniDKistnerOMontomoliE.Emerging influenza strains in the last two decades: a threat of a new pandemic?2015317285Open DOISearch in Google Scholar
World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO. [online] 2016. [cited 2016 May 1]. Available from: http://www.who.int/influenza/human_animal_interface/EN_GIP_20160404cumulativenumberH5N1cases.pdf?ua=1World Health Organizationhttp://www.who.int/influenza/human_animal_interface/EN_GIP_20160404cumulativenumberH5N1cases.pdf?ua=1Search in Google Scholar
Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis. 2010; 201:1644–53.2042322210.1086/652701LangleyJMFrenetteLFergusonLRiffDSheldonERisiGSafety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults2010201164453Search in Google Scholar
Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebocontrolled, randomized study. J Infect Dis. 2011; 203:1729–38.10.1093/infdis/jir172LangleyJMRisiGCaldwellMGildermanLBerwaldBFogartyCDose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebocontrolled, randomized study2011203172938Open DOISearch in Google Scholar
Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One. 2008; 3:e1665.10.1371/journal.pone.000166518301743Leroux-RoelsIBernhardRGérardPDraméMHanonELeroux-RoelsG.Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine20083e1665Open DOISearch in Google Scholar
Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007; 370:580–9.10.1016/S0140-6736(07)61297-517707753Leroux-RoelsIBorkowskiAVanwolleghemTDraméMClementFHonsEAntigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial20073705809Open DOISearch in Google Scholar
Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, et al. Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults. Vaccine. 2009; 27:7428–35.10.1016/j.vaccine.2009.07.102ChuDWHwangSJLimFSOhHMThongcharoenPYangPCImmunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults200927742835Open DOISearch in Google Scholar
Gillard P, Chu DW, Hwang SJ, Yang PC, Thongcharoen P, Lim FS, et al. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults. BMC Infect Dis. 2014; 14:142.10.1186/1471-2334-14-14224628789GillardPChuDWHwangSJYangPCThongcharoenPLimFSLong-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults201414142Open DOISearch in Google Scholar
Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol. 2009; 170:679–86.10.1093/aje/kwp23719679750BastaNEChaoDLHalloranMEMatrajtLLonginiIM Jr.Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States200917067986Open DOISearch in Google Scholar
Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis. 2008; 8:650–8.10.1016/S1473-3099(08)70232-918922487JenningsLCMontoASChanPKSzucsTDNicholsonKG.Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans200886508Open DOISearch in Google Scholar
Díez-Domingo J, Baldó JM, Planelles-Catarino MV, Garcés-Sánchez M, Ubeda I, Jubert-Rosich A, et al. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. Influenza Other Respir Viruses. 2015; 9:68–77.2565287310.1111/irv.12295Díez-DomingoJBaldóJMPlanelles-CatarinoMVGarcés-SánchezMUbedaIJubert-RosichAPhase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination201596877435331925652873Search in Google Scholar
Díez-Domingo J, Garcés-Sánchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J. 2010; 29:e35–46.Díez-DomingoJGarcés-SánchezMBaldóJMPlanellesMVUbedaIJuBertAImmunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study201029e354610.1097/INF.0b013e3181daf92120375709Search in Google Scholar
Rümke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine. 2008; 26:2378–88.1840738210.1016/j.vaccine.2008.02.068RümkeHCBayasJMde JuanesJRCasoCRichardusJHCampinsMSafety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial20082623788818407382Search in Google Scholar
Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, et al. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial. J Infect Dis. 2015; 211:801–10.2529336810.1093/infdis/jiu548KosalaraksaPJeanfreauRFrenetteLDrameMMadariagaMInnisBLAS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial201521180110431948125293368Search in Google Scholar